抗氧化与NMDA受体阻滞剂减轻韩国院外心脏骤停患者缺氧性脑损伤(AWAKE)试验的原理与方法
AWAKE试验为一项II期、多中心、随机、双盲、前瞻性、意向性治疗、安慰剂对照、三臂的安全性与有效性临床试验,旨在评估高剂量或低剂量Neu2000K(选择性NMDA 2B型受体阻滞剂及自由基清除剂)或安慰剂对成年院外心脏骤停(OHCA)复苏后患者缺血性脑损伤的可行性及减轻潜力。主要结局为第3天血神经元特异性烯醇化酶(NSE)水平,计划样本量150例。
要点
- AWAKE试验评估Neu2000K减轻OHCA复苏后缺血性脑损伤的可行性与潜力。
- 主要结局为第3天血NSE水平,样本量估算为150例。
- 试验为II期多中心随机双盲安慰剂对照三臂设计,注册号NCT03651557。
核心结论
- AWAKE试验探索一种新的多靶点神经保护剂用于治疗复苏后的OHCA患者。
研究设计与样本
- 本研究为II期、多中心、随机、双盲、前瞻性、意向性治疗、安慰剂对照、三臂的安全性与有效性临床试验,由申办方发起并获GNT Pharma支持。
- 计划纳入年龄19至80岁、成功复苏的OHCA患者。
主要发现
- 主要结局为第3天血神经元特异性烯醇化酶(NSE)水平。
- 次要结局包括安全性、90%以上参与者在4小时内接受研究药物的有效性定义、至第5天的每日NSE、血S100beta、脑MRI表观扩散系数成像、第5天、第14天和第90天的脑功能分类(CPC)和改良Rankin量表(mRS)。
- 样本量估算假设治疗组(高剂量和低剂量Neu2000K)与对照组的NSE分别为42±80和80±80 μg/L,把握度80%,1型错误率5%,终点前退出率28%,所需样本量为150例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic brain injury is a major hurdle that limits the survival of resuscitated out-of-hospital cardiac arrest (OHCA). METHODS: The aim of this study is to assess the feasibility and potential for reduction of ischemic brain injury in adult OHCA patients treated with high- or low-dose Neu2000K, a selective blocker of N-methyl-D-aspartate (NMDA) type 2B receptor and also a free radical scavenger, or given placebo. This study is a phase II, multicenter, randomized, double-blinded, prospective, intention-to-treat, placebo-controlled, three-armed, safety and efficacy clinical trial. This trial is a sponsor-initiated trial supported by GNT Pharma. Successfully resuscitated OHCA patients aged 19 to 80 years would be included. The primary outcome is blood neuron-specific enolase (NSE) level on the 3rd day. The secondary outcomes are safety, efficacy defined by study drug administration within 4 h in > 90% of participants, daily NSE up to 5th day, blood S100beta, brain MRI apparent diffusion coefficient imaging, cerebral performance category (CPC), and Modified Rankin Scale (mRS) at 5th, 14th, and 90th days. Assuming NSE of 42 ± 80 and 80 ± 80 μg/L in the treatment (high- and low-dose Neu2000K) and control arms with 80% power, a type 1 error rate of 5%, and a 28% of withdrawal prior to the endpoint, the required sample size is 150 patients. DISCUSSION: The AWAKE trial explores a new multi-target neuroprotectant for the treatment of resuscitated OHCA patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT03651557 . Registered on August 29, 2018.
引用
- Choi JH, Chun BJ, Yeom SR, et al. Rationale and methods of the Antioxidant and NMDA receptor blocker Weans Anoxic brain damage of KorEa OHCA patients (AWAKE) trial. Trials. 2022. PMID: 35871083. doi:10.1186/s13063-022-06452-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。